OTCQB Podcast
Nicholas Sosiak joins OTCQB to share how the company crafts the brand and culture to build brand loyalty.
“This ‘sharing of knowledge’ is what makes our industry so awesome”
4/20 special series with Nicholas on insights on the cannabis industry’s developments and prospects.
Is there money to be made in Quebec if cannabis is legalized in the United States?
Discussion with journalist Emile Berube-Lupien on Canada’s place in the recent legislation.
Nick Sosiak on Interview Series from mycannabis
Nicholas takes us through his journey as CFO for Cannara Biotech as he shares insights into the critical success factors that any cannabis entrepreneur should fully grasp.
Nicholas Sosiak today on The Green Peak with Richard Zwicky on Cannabis Radio
Interview with The Green Peak discussing Cannara’s growth strategy and the viability of growing/cultivation in Canada.
Cannabinoid Project’s Podcast with Nick Sosiak
Topics Discussed:
- The current state of the second wave of Canadian LPs
- Shifting focus from cultivation to CPG
- Product formulation trends in Canada
- Canadian cannabis marketing restrictions
- Genetics to keep SKUs fresh and maintain sales volume
Our CFO at The Green Rush Podcast
Listen as they explore the unique Quebec market, Cannara’s business model, why flower remains king and how his team is building immense brand loyalty despite stringent marketing regulations.
Rising High: Exclusive talk with cannabis producer Cannara Biotech.
The piece highlights Q1 earnings, Cannara’s footprint in Quebec and how flower continues to steer the sales in the cannabis market.
Flower Still King Of US
“The market might be shifting to a “second wave” of cannabis cultivators who focus more on the craft side of growing than the large companies that control the bulk of the market.” said Nick Sosiak, Chief Financial Officer.
How Cannara Biotech is dominating the new wave of cannabis cultivation
Our CFO discusses the accelerated retail price compression of cannabis products.
POW Group Interviews Cannara CFO
Discussion about the new Valleyfield facility, market outlook, MD&A, regulations, financials and much more.